Adjunctive immunotherapy of tuberculosis

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 2, 1998, Pages 105-112

  Toossi, Zahra ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cytokine; Immunotherapy; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; GRANULOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CYTOKINES; HUMANS; IMMUNOTHERAPY; MICE; TUBERCULOSIS;

EID: 0031819715     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. World Health Organization Report on the TB Epidemic, WHO/TB (1994) 94: 177.
2. Snider DE, Raviglione M, Kochi A, Global burden of tuberculosis. In: Tuberculosis Pathogenesis, Protection, and Control (ed BR Bloom) 3-11. ASM Press, Washington, DC, 1994.
3. Toossi Z, Cytokine circuits in tuberculosis. Infect Agents Dis (1996) 5: 98-107.
4. Hirsch CS, Ellner JJ, Russell DG, Rich EA, Complement receptor mediated uptake and tumor necrosis α-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol (1994) 152: 743-9.
5. Chan J, Kaufmann SH, Immune mechanisms of protection. In: Tuberculosis Pathogenesis, Protection, and Control (ed BR Bloom) 389-415. ASM Press, Washington, DC, 1994.
6. Orme IM, Anderson P, Boom WH, T-cell response to Mycobacterium tuberculosis. J Infect Dis (1993) 167: 1481-6.
7. Selwyn P, Hartel D, Lewis VA et al, A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med (1989) 320: 545-50.
8. Lucas S, Nelson AM, Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Tuberculosis Pathogenesis, Protection, and Control (ed BR Bloom) 503-513. ASM Press, Washington, DC, 1994.
9. Valone SE, Rich EA, Wallis RS, Ellner J. Expression of tumor necrosis factor α in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun (1988) 56: 3313-15.
10. Wallis RS, Fujiwara H, Ellner JJ, Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. J Immunol (1986) 36: 193-6.
11. Toossi Z, Young TG, Averill LE et al, Induction of transforming growth factor β (TGFβ) by purified protein derivative (PPD) of Mycobacterium tuberculosis. Infect Immun (1995) 63: 224-8.
12. Dahl KE, Shiratsuchi H, Hamilton BD et al, Selective induction of TGFβ in human monocytes by lipoarabinomannan of M. tuberculosis. Infect Immun (1996) 64: 399-405.
13. Cooper MA, Dalton DK, Stewart TA et al, Disseminated tuberculosis in interferon γ gene-disrupted mice. J Exp Med (1993) 178: 2243-7.
14. Flynn JL, Chan J, Triebold KJ et al, An essential role for interferon γ in resistance to Mycobacterium tuberculosis. J Exp Med (1993) 178. 2249-54.
15. Denis M, Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol. Clin Exp Immunol (1991) 84: 200-8.
16. Bermudez LEM, Young LS, Tumor necrosis factor, alone or combined with IL-2 but not IFNγ is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 140: 3006-13.
17. Rook GAW, Taverne J, Leveton C, Steele J, The role of gamma interferon, vitamin D3 metabolites, and tumor necrosis factor in the pathogenesis of tuberculosis. Immunology (1987) 67: 229-34.
18. Hirsch CS, Yoneda T, Ellner JJ et al, Enhancement of intracellular growth of M. tuberculosis in human monocytes by transforming growth factor beta. J Infect Dis (1994) 170: 1229-37.
19. Barnes PF, Lu S, Abrams JS et al, Cytokine production at the site of disease in human tuberculosis. Infect Immun (1993) 61: 3482-9.
20. Hirsch CS, Jerrold JE, Blinkhorn R et al, In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor B. Proc Natl Acad Sci USA (1997) 94: 3926-31.
21. Ding A, Nathan C, Srimal S, Macrophage deactivating factor and TGFβ inhibit of macrophage nitrogen oxide synthesis by IFN-γ. J Immunol (1990) 145: 940-5.
22. Chan J, Xing Y, Magliozzo RS, Bloom BR, Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediaries produced by activated murine macrophages. J Exp Med (1992) 175: 1111-22.
23. Chantry D, Turner M, Abney E, Feldmann M, Modulation of cytokine production by TGFβ. J Immunol (1989) 142: 4295-302.
24. Espevik T, Figari IS, Shalaby MR et al, Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med (1987) 166: 571-6.
25. Rich EA, Panuska JR, Wallis RS et al, Dyscoordinate expression of tumor necrosis α factor by human alveolar macrophages. Am Rev Respir Dis (1989) 139: 1010-15.
26. Toossi Z, Hirsch CS, Hamilton BD et al, Decreased production of transforming growth factor β1 (TGFβ1) in human alveolar macrophages. J Immunol (1996) 156: 3461-8.
27. D'Andrea A, Ma X, Aste-Amezaga M et al, Stimulatory and inhibitory effects of interleukin IL-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells. J Exp Med (1995) 181: 537-46.
28. Barnes PF, Mistry SD, Cooper CL et al, Compartmentalization of a CD4+ T lymphocyte subpopulation in tuberculous pleuritis. J Immunol (1989) 142: 1114-19.
29. Kindler V, Syepino AP, Gran CE et al, The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 56: 731-40
30. Wahl SM, Transforming growth factor beta: a cause and a cure. J Clin Immunol (1992) 2: 61-71.
31. Solis-Herruzo JA, Brenner DA, Chojkier M, Tumor necrosis factor α inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J Biol Chem (1988) 263: 5841-7.
32. Rook GAW, Hernandez-Pando R, The pathogenesis of tuberculosis. Annu Rev Microbiol (1996) 50: 259-84.
33. Sporn MB, Roberts AB, Wakefield LM, Assoian RK, Transforming growth factor βbiological function and chemical structure. Science (1986) 233: 532-5.
34. Kasahari VM, Chen YQ, Su MW et al, Tumor necrosis factor α and interferon γ suppress the activation of human type I collagen gene expression by transforming growth factor β1. J Clin Invest (1990) 86: 1489-94.
35. Wahl SM, Allen JB, Weeks BS et al, Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA (1993) 90: 4577-81.
36. Zugmaier G, Paik S, Wilding G et al, Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res (1991) 51: 3590-4.
37. Anscher MS, Peters WP, Reisenbichler H et al, Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med (1993) 328: 1592-6.
38. Broekelmann TJ, Limper AH, Colby TV, McDonald JA, Transforming growth factor β is present at sites of extracellular matrix gene expression in human pulmonary fibrosis Proc Natl Acad Sci USA (1991) 88: 6642-7.
39. Khalil N, Whitman C, Zuo L et al, Regulation of alveolar macrophage transforming growth factor β secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest (1993) 92: 1812-17.
40. Limper AH, Colby TV, Asakura S, DeRemee RA, Immunohistochemical granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med (1994) 149: 197-202.
41. Toossi Z, Kleinhenz ME, Ellner JJ, Defective interleukin-2 production and responsiveness in human pulmonary tuberculosis. J Exp Med (1986) 163: 1162-72.
42. Torres M, Mendez-Sampiero P, Jimenez-Zamudio L et al, Comparison of the immune response against Mycobacterium tuberculosis antigens between a group of patients with active pulmonary tuberculosis and healthy household contacts. Clin Exp Immunol (1995) 96: 75-8.
43. Hirsch CS, Hussain R, Toossi Z et al, Cross-modulation by transforming growth factor β in human tuberculosis: suppression of antigen-driven blastogenesis and interferon γ production. Proc Natl Acad Sci USA (1996) 93: 3193-8.
44. Toossi Z, Gogate P, Shiratsuchi H et al, Enhanced production of transforming growth factor β (TGFβ) by blood monocytes from patients with active tuberculosis and presence of TGFβ in tuberculous granulomatous lung lesions. J Immunol (1995) 54: 465-73.
45. Zhang M, Gong J, Iyer D et al, T-cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest (1994) 94: 2435-40.
46. Schluger NW, Harkin TJ, Rom WN, Principles of therapy of tuberculosis in the modern era. In: Tuberculosis (ed Rom, Garay) 751-9. Little Brown, New York, 1996.
47. Iseman MD, Cohn DL, Sbarbaro JA, Directly observed treatment of tuberculosis: We can't afford not to try it. N Engl J Med (1993) 328: 576-81.
48. Ellner JJ, Multidrug-resistant tuberculosis. Adv Intern Med (1995) 40: 155-196.
49. Anonymous, Professor Koch's remedy for tuberculosis; Austria. Br Med J (1890) ii: 1490-6.
50. Fowler FF, A preliminary report on the treatment of tuberculosis with turtle vaccine. Tubercle (1930) 12: 12-17.
51. Sphalinger H, Note on treatment of tuberculosis. Lancet (1922) i: 5-8.
52. Holland SM, Einstein MD, Kuhns DB et al, Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon-γ N Eng J Med (1994) 330: 1348-54.
53. Squires KE, Brown ST, Armstrong WF et al, Interferon γ treatment for Mycobacterium avium-intracellulare complex bacillemia in patients with AIDS. J Infect Dis (1992) 166: 686-92.
54. Nathan CF, Kaplan G, Levis WR et al, Local and systemic effects of intradermal recombinant interferon (gamma) in patients with lepromatous leprosy. N Engl J Med (1986) 315: 6-10.
55. Raad I, Hachem R, Leeds N et al, Use of adjunctive treatment with interferon γ in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis (1996) 22: 572-4.
56. Condos R, Rom WN, Schluger NW, Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet (1997) 349: 1513-15.
57. Kaplan G, Kiessling R, Tekiernariam S et al, The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med (1989) 169: 893-907.
58. Kovacs JA, Vogel S, Albert JM et al, Controlled trial of interleukin-2 in patients infected with the human immunodeficiency virus. N Engl J Med (1996) 355: 1350-6.
59. Johnson BJ, Ress SR, Willcox P et al, Clinical and immune responses of tuberculosis patients treated with low-dose EL-2 and multidrug therapy. Cytokines Mol Ther (1995) 1: 185-96.
60. Germann T, Rude E, Interleukin-12. Int Arch Allergy Immunol (1995) 108: 103-12.
61. Kim SJ, Angel P, Lafyatis R et al, Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex. Mol Cell Biol (1990) 10: 1492-6.
62. Border WA, Noble NA, Transforming growth factor β in tissue fibrosis. N Engl J Med (1994) 331: 1286-90.
63. Yamaguchi Y, Mann DM, Ruoslahti E, Negative regulation of transforming growth factor β by the proteoglycan decorin. Nature (1990) 346: 281-3.
64. Border WA, Noble NA, Yamamoto T et al, Natural inhibitor of transforming growth factor β protects against scarring in experimental kidney disease. Nature (1992) 360: 361-4.
65. Flaumenhaft R, Kojima S, Abe M, Rifkin DB, Activation of latent transforming growth factor β. Adv Pharmacol (1993) 24: 51-76.
66. Bottinger EP, Factor VM, Tsang MLS et al, The recombinant proregion of transforming growth factor beta1 (latency associated peptide) inhibits active transforming growth factor beta1 in transgerac mice. Proc Natl Acad Sci USA (1996) 93: 5877-82.
67. Danielpour D, Kim KY, Winokur TS, Sporn MB, Differential regulation of the expression of transforming growth factor βs 1 and 2 by retinoic acid, epidermal growth factor, and dexamethasone in NRK-49F and A5449 cells. J Cell Physiol (1991) 148: 235-9.
68. Baeuerle P, Baichwal VR, NF-ΚB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol (1997) 65: 111-37.
69. Scheinman R, Cogswell PC, Lofquist AK et al, Role of transcriptional activation of IΚBα in mediation of immunosuppression of glucocorticoids. Science (1995) 270: 283-6.
70. Tavares JL, Wangoo A, Dilworth P et al, Thalidomide reduces tumour necrosis factor alpha production by human alveolar macrophages. Respir Med (1997) 91: 31-9.
71. Zabel P, Schade FU, Schlaak M, Inhibition of endogenous TNF formation by pentoxyfylline. Immunobiology (1993) 187: 447-63.
72. Johnson JR, Taylor BC, Morrissey JF et al, Corticosteroids in pulmonary tuberculosis. Am Rev Respir Dis (1965) 92: 376-91.
73. Senderovitz T, Viskum K, Costicosteroids and tuberculosis. Respir Med (1994) 88: 561-9.
74. Muthuswamy P, Hu YC, Carasso B et al, Prednisone as adjunctive therapy in the management of pulmonary tuberculosis report of 12 cases and review of the literature. Chest (1995) 107: 1621-30.
75. Vicenzi E, Biswas P, Mengozzi M, Poli G, Role of pro-inflammatory cytokines and β-chemokines in controlling HIV replication. J Leuk Biol (1997) 62: 34-40.
76. Tramontana JM, Utaipat U, Molly A et al, Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med (1995) 1: 384-97.
77. Palmer CE, Long MW, Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Resp Dis (1996) 94: 553-68.
78. Pitulle C, Dorsch M, Kazda J et al, Phylogeny of rapidly growing members of the genus mycobacterium. Int J Syst Bacteriol (1992) 42: 337-43.
79. von Ryan CF, Arbeit RD, Yeaman G et al, Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series. Clin Infect Dis (1997) 24: 843-8.
80. Onyebujoh PC, Abdulmumini S, Robinson GA et al, Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med (1995) 89: 199-207.
81. Corlan E, Marica C, Macavei C et al, Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med (1997) 91: 21-9.
82. Corlan E, Marica C, Macavei C et al, Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly diagnosed pulmonary disease. Respir Med (1997) 91: 13-19.
83. Etemadi A, Farid R, Stanford JL, Immunotherapy for drug resistant tuberculosis. Lancet (1992) 340: 1360-1.
84. 2 vitamin D3 production by T lymphocytes and alveolar macrophates recovered by lavage from normocalcemic patients with tuberculosis. J Clin Invest (1990) 85: 1588-93.
85. Kruetz M, Andreesen R, Induction of human monocyte to macrophage maturation by 1,25 dihydroxyvitamin D3. Blood (1990) 76: 2457-61.
86. Rigby WF, Yirinec B, Oldershaw RL et al, Comparison of the effects of 1,25 dihydroxy vitamin D3 on T lymphocyte subpopulations. Eur J Immunol (1987) 17: 563-6.